These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 24913170)

  • 1. Identification of a novel clone, ST736, among Enterococcus faecium clinical isolates and its association with daptomycin nonsusceptibility.
    Wang G; Kamalakaran S; Dhand A; Huang W; Ojaimi C; Zhuge J; Yee LL; Mayigowda P; Surendraiah PK; Dimitrova N; Fallon JT
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4848-54. PubMed ID: 24913170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution and mutations predisposing to daptomycin resistance in vancomycin-resistant Enterococcus faecium ST736 strains.
    Wang G; Yu F; Lin H; Murugesan K; Huang W; Hoss AG; Dhand A; Lee LY; Zhuge J; Yin C; Montecalvo M; Dimitrova N; Fallon JT
    PLoS One; 2018; 13(12):e0209785. PubMed ID: 30576392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single-center experience with infections due to daptomycin-nonsusceptible Enterococcus faecium in liver transplant recipients.
    Lewis JD; Enfield KB; Cox HL; Mathers AJ; Sifri CD
    Transpl Infect Dis; 2016 Jun; 18(3):341-53. PubMed ID: 26953719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of enterococci to daptomycin is dependent upon testing methodology.
    Bryant KA; Roberts AL; Rupp ME; Anderson JR; Lyden ER; Fey PD; Van Schooneveld TC
    Diagn Microbiol Infect Dis; 2013 Aug; 76(4):497-501. PubMed ID: 23719086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De novo daptomycin-nonsusceptible enterococcal infections.
    Kelesidis T; Humphries R; Uslan DZ; Pegues D
    Emerg Infect Dis; 2012 Apr; 18(4):674-6. PubMed ID: 22469288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of Inoculum Effect on the Efficacy of Daptomycin Monotherapy and in Combination with β-Lactams against Daptomycin-Susceptible Enterococcus faecium Harboring LiaSR Substitutions.
    Kebriaei R; Rice SA; Singh KV; Stamper KC; Dinh AQ; Rios R; Diaz L; Murray BE; Munita JM; Tran TT; Arias CA; Rybak MJ
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29760141
    [No Abstract]   [Full Text] [Related]  

  • 7. Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints.
    Munita JM; Panesso D; Diaz L; Tran TT; Reyes J; Wanger A; Murray BE; Arias CA
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4354-9. PubMed ID: 22664970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of high-level daptomycin resistance in Enterococcus faecium during daptomycin therapy is associated with limited mutations in the bacterial genome.
    Kelesidis T; Tewhey R; Humphries RM
    J Antimicrob Chemother; 2013 Aug; 68(8):1926-8. PubMed ID: 23580562
    [No Abstract]   [Full Text] [Related]  

  • 9. Utilizing genomic analyses to investigate the first outbreak of vanA vancomycin-resistant Enterococcus in Australia with emergence of daptomycin non-susceptibility.
    Douglas AP; Marshall C; Baines SL; Ritchie D; Szer J; Madigan V; Chan HT; Ballard SA; Howden BP; Buising K; Slavin MA
    J Med Microbiol; 2019 Mar; 68(3):303-308. PubMed ID: 30663951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure of daptomycin β-Lactam combination therapy to prevent resistance emergence in Enterococcus faecium.
    Menon V; Davis R; Shackel N; Espedido BA; Beukers AG; Jensen SO; van Hal SJ
    Diagn Microbiol Infect Dis; 2018 Feb; 90(2):120-122. PubMed ID: 29195768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of a daptomycin-non-susceptible Enterococcus faecium strain that encodes mutations in DNA repair genes after high-dose daptomycin therapy.
    Matono T; Hayakawa K; Hirai R; Tanimura A; Yamamoto K; Fujiya Y; Mawatari M; Kutsuna S; Takeshita N; Mezaki K; Ohmagari N; Miyoshi-Akiyama T
    BMC Res Notes; 2016 Apr; 9():197. PubMed ID: 27036708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mutation in the glycosyltransferase gene lafB causes daptomycin hypersusceptibility in Enterococcus faecium.
    Mello SS; Van Tyne D; Lebreton F; Silva SQ; Nogueira MCL; Gilmore MS; Camargo ILBC
    J Antimicrob Chemother; 2020 Jan; 75(1):36-45. PubMed ID: 31586422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of daptomycin use with resistance development in Enterococcus faecium bacteraemia-a 7-year individual and population-based analysis.
    Egli A; Schmid H; Kuenzli E; Widmer AF; Battegay M; Plagge H; Frei R; Achermann R; Weisser M
    Clin Microbiol Infect; 2017 Feb; 23(2):118.e1-118.e7. PubMed ID: 27746397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular analysis and distribution of multidrug-resistant Enterococcus faecium isolates belonging to clonal complex 17 in a tertiary care center in Mexico City.
    Ochoa SA; Escalona G; Cruz-Córdova A; Dávila LB; Saldaña Z; Cázares-Domímguez V; Eslava CA; López-Martínez B; Hernández-Castro R; Aquino-Jarquin G; Xicohtencatl-Cortes J
    BMC Microbiol; 2013 Dec; 13():291. PubMed ID: 24330424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-genome analysis of a daptomycin-susceptible enterococcus faecium strain and its daptomycin-resistant variant arising during therapy.
    Tran TT; Panesso D; Gao H; Roh JH; Munita JM; Reyes J; Diaz L; Lobos EA; Shamoo Y; Mishra NN; Bayer AS; Murray BE; Weinstock GM; Arias CA
    Antimicrob Agents Chemother; 2013 Jan; 57(1):261-8. PubMed ID: 23114757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of Minimum Inhibitory Concentration in Clinical Outcomes of Enterococcus faecium Bacteremia Treated With Daptomycin: Is it Time to Change the Breakpoint?
    Shukla BS; Shelburne S; Reyes K; Kamboj M; Lewis JD; Rincon SL; Reyes J; Carvajal LP; Panesso D; Sifri CD; Zervos MJ; Pamer EG; Tran TT; Adachi J; Munita JM; Hasbun R; Arias CA
    Clin Infect Dis; 2016 Jun; 62(12):1514-1520. PubMed ID: 27045126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Tedizolid
    Carvalhaes CG; Sader HS; Flamm RK; Streit JM; Mendes RE
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular epidemiology of vancomycin-resistant enterococcal bacteraemia: results from the Canadian Nosocomial Infection Surveillance Program, 1999-2009.
    McCracken M; Wong A; Mitchell R; Gravel D; Conly J; Embil J; Johnston L; Matlow A; Ormiston D; Simor AE; Smith S; Du T; Hizon R; Mulvey MR;
    J Antimicrob Chemother; 2013 Jul; 68(7):1505-9. PubMed ID: 23524466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of tedizolid on clinical Enterococcus isolates: in vitro activity, distribution of virulence factor, resistance genes and multilocus sequence typing.
    Bai B; Hu K; Li H; Yao W; Li D; Chen Z; Cheng H; Zheng J; Pan W; Deng M; Liu X; Lin Z; Deng Q; Yu Z
    FEMS Microbiol Lett; 2018 Feb; 365(3):. PubMed ID: 29390078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of Daptomycin against Enterococcus faecium and Enterococcus faecalis in the Murine Thigh Infection Model.
    Kidd JM; Abdelraouf K; Asempa TE; Humphries RM; Nicolau DP
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.